During REFLECT study enrollment for patients with locally advanced and/or metastatic NSCLC harboring an EGFR mutation, the first-line treatment includes first-generation EGFR-tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, second-generation EGFR-TKIs such as afatinib and dacomitinib, and the newest third-generation EGFR-TKI osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.